Antagonistic effects of sodium butyrate and N-(4-hydroxyphenyl)-retinamide on prostate cancer
- PMID: 17401464
- PMCID: PMC1838581
- DOI: 10.1593/neo.06766
Antagonistic effects of sodium butyrate and N-(4-hydroxyphenyl)-retinamide on prostate cancer
Abstract
Butyrates and retinoids are promising antineoplastic agents. Here we analyzed effects of sodium butyrate and N-(4-hydroxyphenyl)-retinamide (4-HPR) on prostate cancer cells as monotherapy or in combination in vitro and in vivo. Sodium butyrate and 4-HPR induced concentration-dependent growth inhibition in prostate cancer cells in vitro. The isobologram analysis revealed that sodium butyrate and 4-HPR administered together antagonize effects of each other. For the in vivo studies, a water-soluble complex (4-HPR with a cyclodextrin) was created. A single dose of sodium butyrate and 4-HPR showed a peak level in chicken plasma within 30 minutes. Both compounds induced inhibition of proliferation and apoptosis in xenografts of the chicken chorioallantoic membrane. Analysis of the cytotoxic effects of the drugs used in combination demonstrated an antagonistic effect on inhibition of proliferation and on induction of apoptosis. Prolonged jun N-terminal kinase phosphorylation induced by sodium butyrate and 4-HPR was strongly attenuated when both compounds were used in combination. Both compounds induced inhibition of NF-kappaB. This effect was strongly antagonized in LNCaP cells when the compounds were used in combination. These results indicate that combinational therapies have to be carefully investigated due to potential antagonistic effects in the clinical setting despite promising results of a monotherapy.
Figures






Similar articles
-
Contributions of mitogen-activated protein kinase and nuclear factor kappa B to N-(4-hydroxyphenyl)retinamide-induced apoptosis in prostate cancer cells.Mol Carcinog. 2002 Nov;35(3):127-37. doi: 10.1002/mc.10084. Mol Carcinog. 2002. PMID: 12410564
-
Requirement of c-jun for testosterone-induced sensitization to N-(4-hydroxyphenyl)retinamide-induced apoptosis.Mol Carcinog. 2003 Mar;36(3):115-22. doi: 10.1002/mc.10107. Mol Carcinog. 2003. PMID: 12619033
-
c-Jun N-terminal kinase mediates apoptotic signaling induced by N-(4-hydroxyphenyl)retinamide.Mol Pharmacol. 1999 Dec;56(6):1271-9. doi: 10.1124/mol.56.6.1271. Mol Pharmacol. 1999. PMID: 10570055
-
Inhibition of N-(4-hydroxyphenyl)retinamide-induced autophagy at a lower dose enhances cell death in malignant glioma cells.Carcinogenesis. 2008 Mar;29(3):600-9. doi: 10.1093/carcin/bgm264. Epub 2008 Jan 3. Carcinogenesis. 2008. PMID: 18174255
-
Butyrate as a differentiating agent: pharmacokinetics, analogues and current status.Cancer Lett. 1994 Apr 1;78(1-3):1-5. doi: 10.1016/0304-3835(94)90023-x. Cancer Lett. 1994. PMID: 8180951 Review.
Cited by
-
Butyrate Suppresses the Proliferation of Colorectal Cancer Cells via Targeting Pyruvate Kinase M2 and Metabolic Reprogramming.Mol Cell Proteomics. 2018 Aug;17(8):1531-1545. doi: 10.1074/mcp.RA118.000752. Epub 2018 May 8. Mol Cell Proteomics. 2018. PMID: 29739823 Free PMC article.
-
Chronic inflammation and cancer: potential chemoprevention through nuclear factor kappa B and p53 mutual antagonism.J Inflamm (Lond). 2014 Aug 9;11:23. doi: 10.1186/1476-9255-11-23. eCollection 2014. J Inflamm (Lond). 2014. PMID: 25152696 Free PMC article. Review.
-
Neoplasia: the second decade.Neoplasia. 2008 Dec;10(12):1314-24. doi: 10.1593/neo.81372. Neoplasia. 2008. PMID: 19048110 Free PMC article.
-
MS-275 synergistically enhances the growth inhibitory effects of RAMBA VN/66-1 in hormone-insensitive PC-3 prostate cancer cells and tumours.Br J Cancer. 2008 Apr 8;98(7):1234-43. doi: 10.1038/sj.bjc.6604295. Epub 2008 Mar 18. Br J Cancer. 2008. PMID: 18349838 Free PMC article.
-
RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease.Neoplasia. 2009 Sep;11(9):956-63. doi: 10.1593/neo.09694. Neoplasia. 2009. PMID: 19724689 Free PMC article.
References
-
- Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer. 1993;71:1098–1109. - PubMed
-
- Graham J. Chemotherapy for metastatic disease: current status. Clin Oncol (R Coll Radiol) 2005;17:527–578. - PubMed
-
- Silvestris N, Leone B, Numico G, Lorusso V, De Lena M. Present status and perspectives in the treatment of hormone-refractory prostate cancer. Oncology. 2005;69:273–282. - PubMed
-
- Chen JS, Faller DV, Spanjaard RA. Short-chain fatty acid inhibitors of histone deacetylases: promising anticancer therapeutics? Curr Cancer Drug Targets. 2003;3:219–236. - PubMed
-
- Maier S, Reich E, Martin R, Bachem M, Altug V, Hautmann RE, Gschwend JE. Tributyrin induces differentiation, growth arrest and apoptosis in androgen-sensitive and androgen-resistant human prostate cancer cell lines. Int J Cancer. 2000;88:245–251. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous